{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:07:35Z","timestamp":1790536055850,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"23-24","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Chimeric antigen receptor (CAR) T\u2011cells are genetically engineered to give T\u2011cells the ability to attack specific cancer cells, and to improve outcome of patients with refractory\/relapsed aggressive B\u2011cell malignancies. To date, several CAR T\u2011cell products are approved and additional products with similar indication or extended to other malignancies are currently being evaluated. Side effects of CAR T\u2011cell treatment are potentially severe or even life-threatening immune-related toxicities, specifically cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Consequently, medical emergency teams (MET) are increasingly involved in the assessment and management of CAR T\u2011cell recipients. This article describes the principles of CAR T\u2011cell therapy and summarizes the main complications and subsequent therapeutic interventions aiming to provide a\u00a0survival guide for METs with a\u00a0proposed management algorithm.<\/jats:p>","DOI":"10.1007\/s00508-021-01948-2","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T22:12:37Z","timestamp":1633644757000},"page":"1318-1325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["CAR T-cell therapy and critical care"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3206-9112","authenticated-orcid":false,"given":"Anna S.","family":"Messmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yok-Ai","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Banz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"issue":"7776","key":"1948_CR1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria\u00a0O, Cornen\u00a0S, Da\u00ebron\u00a0M, et\u00a0al. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45\u201356.","journal-title":"Nature"},{"issue":"5","key":"1948_CR2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","volume":"10","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer\u00a0JN, Rosenberg\u00a0SA. Treating B\u2011cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267\u201376.","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"1948_CR3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu\u00a0SS, Locke\u00a0FL, Bartlett\u00a0NL, et al. Axicabtagene ciloleucel CAR T\u2011cell therapy in refractory large B\u2011cell lymphoma. N\u00a0Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"1948_CR4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster\u00a0SJ, Bishop\u00a0MR, Tam\u00a0CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B\u2011cell lymphoma. N\u00a0Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"14","key":"1948_CR5","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang\u00a0M, Munoz\u00a0J, Goy\u00a0A, et al. KTE-X19 CAR T\u2011cell therapy in relapsed or refractory mantle-cell lymphoma. N\u00a0Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"5","key":"1948_CR6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude\u00a0SL, Laetsch\u00a0TW, Buechner\u00a0J, et al. Tisagenlecleucel in children and young adults with B\u2011cell lymphoblastic leukemia. N\u00a0Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"1948_CR7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno\u00a0JN, Kochenderfer\u00a0JN. Chimeric antigen receptor T\u2011cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31\u201346.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1948_CR8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi\u00a0NC, Anderson\u00a0LD Jr., Shah\u00a0N, et\u00a0al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N\u00a0Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"1948_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu\u00a0SS, Tummala\u00a0S, Kebriaei\u00a0P, et al. Chimeric antigen receptor T\u2011cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1948_CR10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee\u00a0DW, Santomasso\u00a0BD, Locke\u00a0FL, et\u00a0al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"1948_CR11","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno\u00a0JN, Kochenderfer\u00a0JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"},{"issue":"5","key":"1948_CR12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park\u00a0JH, Rivi\u00e8re\u00a0I, Gonen\u00a0M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N\u00a0Engl J Med. 2018;378(5):449\u201359.","journal-title":"N Engl J Med"},{"key":"1948_CR13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","volume":"16","author":"S Tyagarajan","year":"2020","unstructured":"Tyagarajan\u00a0S, Spencer\u00a0T, Smith\u00a0J. Optimizing CAR\u2011T cell manufacturing processes during pivotal clinical trials. Mol Ther Methods Clin Dev. 2020;16:136\u201344.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1948_CR14","unstructured":"MD Anderson Cancer Center. CARTOX app Version 2.3. https:\/\/play.google.com\/store\/apps\/details?id=org.mdanderson.cartox&hl=de_CH&gl=US; https:\/\/apps.apple.com\/ch\/app\/cartox\/id1464005828?l=en."},{"issue":"S1","key":"1948_CR15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","volume":"37","author":"SS Neelapu","year":"2019","unstructured":"Neelapu\u00a0SS. Managing the toxicities of CAR T\u2011cell therapy. Hematol Oncol. 2019;37(S1):48\u201352.","journal-title":"Hematol Oncol"},{"issue":"2","key":"1948_CR16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee\u00a0DW, Gardner\u00a0R, Porter\u00a0DL, et\u00a0al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"1","key":"1948_CR17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen\u00a0A, Godel\u00a0P, Subklewe\u00a0M, et al. Cytokine release syndrome. J\u00a0Immunother Cancer. 2018;6(1):56.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"1948_CR18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso\u00a0BD, Park\u00a0JH, Salloum\u00a0D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T\u2011cell therapy in patients with B\u2011cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958\u201371.","journal-title":"Cancer Discov"},{"issue":"27","key":"1948_CR19","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil\u00a0LJ, Jain\u00a0MD, Feng\u00a0L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B\u2011cell lymphoma: results from the US lymphoma CAR T consortium. J\u00a0Clin Oncol. 2020;38(27):3119\u201328.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1948_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke\u00a0FL, Ghobadi\u00a0A, Jacobson\u00a0CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B\u2011cell lymphoma (ZUMA-1): a\u00a0single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1948_CR21","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus\u00a0MV, Alexander\u00a0S, Bishop\u00a0MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J\u00a0Immunother Cancer. 2020;8(2):e1511.","journal-title":"J Immunother Cancer"},{"issue":"15","key":"1948_CR22","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","volume":"36","author":"JS Abramson","year":"2018","unstructured":"Abramson\u00a0JS, Gordon\u00a0LI, Palomba\u00a0ML, et\u00a0al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL. J\u00a0Clin Oncol. 2018;36(15):7505.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1948_CR23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00134-017-4943-5","volume":"44","author":"P Godel","year":"2018","unstructured":"Godel\u00a0P, Shimabukuro-Vornhagen\u00a0A, von Bergwelt-Baildon\u00a0M. Understanding cytokine release syndrome. Intensive Care Med. 2018;44(3):371\u20133.","journal-title":"Intensive Care Med"},{"issue":"8","key":"1948_CR24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","volume":"8","author":"T Tanaka","year":"2016","unstructured":"Tanaka\u00a0T, Narazaki\u00a0M, Kishimoto\u00a0T. Immunotherapeutic implications of IL\u20116 blockade for cytokine storm. Immunotherapy. 2016;8(8):959\u201370.","journal-title":"Immunotherapy"},{"issue":"177","key":"1948_CR25","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens\u00a0RJ, Davila\u00a0ML, Riviere\u00a0I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.","journal-title":"Sci Transl Med"},{"issue":"7","key":"1948_CR26","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","volume":"94","author":"U Winkler","year":"1999","unstructured":"Winkler\u00a0U, Jensen\u00a0M, Manzke\u00a0O, et al. Cytokine-release syndrome in patients with B\u2011cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217\u201324.","journal-title":"Blood"},{"issue":"26","key":"1948_CR27","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey\u00a0DT, Rheingold\u00a0SR, Maude\u00a0SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154\u20137.","journal-title":"Blood"},{"issue":"21","key":"1948_CR28","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay\u00a0KA, Hanafi\u00a0LA, Li\u00a0D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T\u2011cell therapy. Blood. 2017;130(21):2295\u2013306.","journal-title":"Blood"},{"issue":"7","key":"1948_CR29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jcyt.2017.04.001","volume":"19","author":"N Singh","year":"2017","unstructured":"Singh\u00a0N, Hofmann\u00a0TJ, Gershenson\u00a0Z, et al. Monocyte lineage-derived IL\u20116 does not affect chimeric antigen receptor T\u2011cell function. Cytotherapy. 2017;19(7):867\u201380.","journal-title":"Cytotherapy"},{"issue":"6","key":"1948_CR30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli\u00a0M, Camisa\u00a0B, Barbiera\u00a0G, et al. Monocyte-derived IL\u20111 and IL\u20116 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348.","journal-title":"Nat Med"},{"issue":"2","key":"1948_CR31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy\u00a0LB, Salama\u00a0AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86\u2013104.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"1948_CR32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust\u00a0J, Hay\u00a0KA, Hanafi\u00a0LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR\u2011T cells. Cancer Discov. 2017;7(12):1404\u201319.","journal-title":"Cancer Discov"},{"issue":"1","key":"1948_CR33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","volume":"9","author":"Y Hu","year":"2016","unstructured":"Hu\u00a0Y, Sun\u00a0J, Wu\u00a0Z, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J\u00a0Hematol Oncol. 2016;9(1):70.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1948_CR34","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","volume":"8","author":"\u00c9 Azoulay","year":"2021","unstructured":"Azoulay \u00c9, Castro\u00a0P, Maamar\u00a0A, et al. Outcomes in patients treated with chimeric antigen receptor T\u2011cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematol. 2021;8(5):e355\u2013e64.","journal-title":"Lancet Haematol"},{"issue":"1","key":"1948_CR35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill\u00a0JA, Li\u00a0D, Hay\u00a0KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T\u2011cell immunotherapy. Blood. 2018;131(1):121\u201330.","journal-title":"Blood"},{"issue":"19","key":"1948_CR36","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"SC Howard","year":"2011","unstructured":"Howard\u00a0SC, Jones\u00a0DP, Pui\u00a0C\u2011H. The tumor lysis syndrome. N\u00a0Engl J Med. 2011;364(19):1844\u201354.","journal-title":"N Engl J Med"},{"issue":"4","key":"1948_CR37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","volume":"95","author":"SC Howard","year":"2016","unstructured":"Howard\u00a0SC, Trifilio\u00a0S, Gregory\u00a0TK, et\u00a0al. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a\u00a0systematic review. Ann Hematol. 2016;95(4):563\u201373.","journal-title":"Ann Hematol"},{"issue":"2","key":"1948_CR38","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","volume":"3","author":"JG Borrega","year":"2019","unstructured":"Borrega\u00a0JG, G\u00f6del\u00a0P, R\u00fcger\u00a0MA, Onur \u00d6A, Shimabukuro-Vornhagen\u00a0A, Kochanek\u00a0M, et al. In the eye of the storm: immune-mediated toxicities associated with CAR\u2011T cell therapy. Hemasphere. 2019;3(2):e191.","journal-title":"Hemasphere"},{"issue":"2","key":"1948_CR39","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.16155","volume":"187","author":"H Hashmi","year":"2019","unstructured":"Hashmi\u00a0H, Bachmeier\u00a0C, Chavez\u00a0JC, et\u00a0al. Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. Br J Haematol. 2019;187(2):e35\u2013e8.","journal-title":"Br J Haematol"},{"key":"1948_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-79026-8_14","author":"EM Eloseily","year":"2018","unstructured":"Eloseily\u00a0EM, Cron\u00a0RQ. Macrophage activation syndrome. Microbiome Rheum Dis Infect. 2018; https:\/\/doi.org\/10.1007\/978-3-319-79026-8_14.","journal-title":"Microbiome Rheum Dis Infect"},{"issue":"5","key":"1948_CR41","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","volume":"142","author":"DB Rubin","year":"2019","unstructured":"Rubin\u00a0DB, Danish\u00a0HH, Ali\u00a0AB, et al. Neurological toxicities associated with chimeric antigen receptor T\u2011cell therapy. Brain. 2019;142(5):1334\u201348.","journal-title":"Brain"},{"issue":"3","key":"1948_CR42","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/WCO.0000000000000686","volume":"32","author":"C Perrinjaquet","year":"2019","unstructured":"Perrinjaquet\u00a0C, Desbaillets\u00a0N, Hottinger\u00a0AF. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T\u2011cell therapy. Curr Opin Neurol. 2019;32(3):500\u201310.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"1948_CR43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/CCM.0000000000004087","volume":"48","author":"C Gutierrez","year":"2020","unstructured":"Gutierrez\u00a0C, McEvoy\u00a0C, Munshi\u00a0L, et\u00a0al. Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. Crit Care Med. 2020;48(1):10\u201321.","journal-title":"Crit Care Med"},{"key":"1948_CR44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcrc.2020.04.008","volume":"58","author":"C Gutierrez","year":"2020","unstructured":"Gutierrez\u00a0C, Brown\u00a0ART, Herr\u00a0MM, et al. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: surveying intensive care unit practices in the management of CAR T\u2011cell associated toxicities. J\u00a0Crit Care. 2020;58:58\u201364.","journal-title":"J Crit Care"},{"issue":"1","key":"1948_CR45","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1007\/s00134-013-3093-7","volume":"40","author":"TM Zytoun","year":"2014","unstructured":"Zytoun\u00a0TM, Mahrous\u00a0AA, Megahed\u00a0MM, et al. Colloid versus crystalloid in septic neutropenic patients using serum neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute renal failure. Intensive Care Med. 2014;40(1):S111.","journal-title":"Intensive Care Med"},{"issue":"20","key":"1948_CR46","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia\u00a0P, Jordan\u00a0JT, Forst\u00a0DA, et\u00a0al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212\u201321.","journal-title":"Blood"},{"issue":"2","key":"1948_CR47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","volume":"20","author":"SL Maude","year":"2014","unstructured":"Maude\u00a0SL, Barrett\u00a0D, Teachey\u00a0DT, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer\u00a0J. 2014;20(2):119\u201322.","journal-title":"Cancer J"},{"issue":"24","key":"1948_CR48","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","volume":"134","author":"RA Gardner","year":"2019","unstructured":"Gardner\u00a0RA, Ceppi\u00a0F, Rivers\u00a0J, et al. Preemptive mitigation of CD19 CAR T\u2011cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134(24):2149\u201358.","journal-title":"Blood"},{"issue":"15","key":"1948_CR49","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2019.37.15_suppl.7006","volume":"37","author":"BD Shah","year":"2019","unstructured":"Shah\u00a0BD, Bishop\u00a0MR, Oluwole\u00a0OO, et al. End of phase I results of ZUMA\u20113, a\u00a0phase 1\/2\u00a0study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL). J\u00a0Clin Oncol. 2019;37(15):7006.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1948_CR50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","volume":"10","author":"S Liu","year":"2020","unstructured":"Liu\u00a0S, Deng\u00a0B, Yin\u00a0Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR\u2011T cells for B\u2011cell acute lymphoblastic leukemia. Blood Cancer\u00a0J. 2020;10(2):15.","journal-title":"Blood Cancer J"},{"issue":"16","key":"1948_CR51","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp\u00a0SA, Kalos\u00a0M, Barrett\u00a0D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N\u00a0Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"key":"1948_CR52","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant\u00a0CL, Jackson\u00a0HJ, Brentjens\u00a0RJ, et al. Toxicity and management in CAR T\u2011cell therapy. Mol Ther Oncolytics. 2016;3:16011.","journal-title":"Mol Ther Oncolytics"},{"issue":"7","key":"1948_CR53","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","volume":"4","author":"SJ Schuster","year":"2020","unstructured":"Schuster\u00a0SJ, Maziarz\u00a0RT, Rusch\u00a0ES, et\u00a0al. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020;4(7):1432\u20139.","journal-title":"Blood Adv"},{"issue":"13","key":"1948_CR54","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","volume":"4","author":"P Strati","year":"2020","unstructured":"Strati\u00a0P, Ahmed\u00a0S, Kebriaei\u00a0P, et al. Clinical efficacy of anakinra to mitigate CAR T\u2011cell therapy-associated toxicity in large B\u2011cell lymphoma. Blood Adv. 2020;4(13):3123\u20137.","journal-title":"Blood Adv"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01948-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-021-01948-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01948-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T09:32:50Z","timestamp":1639474370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-021-01948-2"}},"subtitle":["A\u00a0survival guide for medical emergency teams"],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":54,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1948"],"URL":"https:\/\/doi.org\/10.1007\/s00508-021-01948-2","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"3 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S.\u00a0Messmer, Y.-A.\u00a0Que, C.\u00a0Schankin, Y.\u00a0Banz, U.\u00a0Bacher, U.\u00a0Novak and T.\u00a0Pabst declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}